ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Company codeNDRA
Company nameENDRA Life Sciences Inc
IPO dateJun 28, 2017
Founded at2007
CEOMr. Alexander Y. Tokman
Number of employees21
Security typeOrdinary Share
Fiscal year-endJun 28
Address3600 Green Ct Ste 350
CityANN ARBOR
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code48105-2440
Phone17343350468
Websitehttps://www.endrainc.com/
Company codeNDRA
IPO dateJun 28, 2017
Founded at2007
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data